Medical articles today

/* 728x15, */

SYNTAX Substudy Shows Convinced Outcomes For Left Leading Patients Treated With TAXUS R Express2 R Stent System

/* 468x60, */

Boston Scientific Gathering (NYSE: BSX) announced positive outcomes from a substudy of patients with left main coronary disease who were treated with the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System. SYNTAX-LE MANS is a substudy of the landmark SYNTAX trial, the first randomized, controlled clinical research to compare percutaneous coronary intervention (PCI) using the TAXUS Stent to coronary artery bypass scion (CABG) surgery in patients with left main disease and/or significant narrowing of all three coronary arteries (three-vessel disease). The substudy material were presented by A. Pieter Kappetein, M.D., Ph.D., at the annual EuroPCR Scientific Program in Barcelona.
SYNTAX-LE MANS compares unpunctual angiographic and clinical outcomes in 263 patients with left main disease (149 treated with the TAXUS Stent and 114 treated with CABG). It is designed to assess 15-month patency (vessel openness) and the safety of stents and grafts in this high-risk population; it includes separate primary endpoints for each treatment arm. For PCI patients, the primary endpoint is the percentage of long-term patency (defined here as <50% stenosis) of the treated lesion sites. For CABG patients, the essential endpoint is the ratio of obstructed/occluded grafts (defined here as greater than or identical to 50% stenosis) to complete placed grafts. Results were presented separately for everyone group, and no formal statistical inferences between the two groups were prepared due to the deviating primary endpoints. Results were besides broken out by left main lesion location, including distal and non-distal.
For those patients receiving a TAXUS Stent, the patency rate for the treated lesion was 92 percent. Restenosis was besides familiar with distal lesions (90% patency) compared with non-distal lesions (98% patency). Reported in-stent slow loss was low at 0.2 mm for non-distal lesions. The reported 15-month MACCE ratio (all-cause death, stroke, myocardial infarction and revascularization) for the TAXUS Stent patients was 13 percent, driven primarily by a nine percent repeat revascularization rate.
For CABG patients, the overall obstruction/occlusion ratio at 15 months was 16 percent, with six percent of grafts obstructed in the compass of in a superior way than or equal to 50% to <100%, and 10 percent of grafts occluded 100%. On a per patient basis, the obstruction/occlusion ratio was 27 percent, with nine percent of patients having a graft obstructed in the greater than or equal to 50% to <100% range and 18 percent of patients having a graft occluded 100%. The reported MACCE scale for CABG patients at 15 months was nine percent.
"The information announced nowadays from SYNTAX-LE MANS will offer earnest insights for doctors as they evaluate treatment options for challenging left main patients," said Keith Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "We are encouraged by the high rise stent patency proportion at 15 months, which increases our confidence in the application of PCI in this high-risk population. The results support formerly announced outcomes with PCI and CABG in patients with left main disease."
The safety and effectiveness of the TAXUS Express2 Stent System own not been established in patients with left main or three-vessel disease.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a wide reach of interventional medical specialties.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the heart of Abbreviate 21E of the Securities Transform Act of 1934. Forward-looking statements may be identified by contents adoration "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using hash available to us at the generation and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or provided trustworthy risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, keep affected and in the future (together with other factors) could act on our ability to gadget our bag strategy and may agency actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: imminent economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial mart conditions; and, future dodge decisions mythical by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a as well file and description of these and other important risks and uncertainties that may impress our forthcoming operations, glare Stuff I, Object 1A- Risk Factors in our most advanced Annual Announcement on Cut 10-K filed with the Securities and Exchange Commission, which we may update in Bit II, Tool 1A - Risk Factors in Quarterly Reports on Cast 10-Q we have filed or testament string thereafter. We disclaim any intention or obligation to publicly rejuvenate or revise any forward-looking statements to rebound any modify in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may prevail the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Source: Boston Scientific Corporation
/* 468x60, */


patients, patients left, cabg patients, patients treated, leading patients, patients graft, percent patients, patients said, patients overall, patients receiving
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy